Integration of eQTL and multi-omics comprehensive analysis of triacylglycerol synthase 1 (TGS1) as a prognostic and immunotherapeutic biomarker across pan-cancer

被引:0
|
作者
Qiu, Xinhui [1 ,2 ]
Yang, Ziqing [3 ]
Zhang, Chengyuan [1 ,2 ]
Ma, Anquan [3 ]
Zong, Xiaoyang [3 ]
Chen, Chaojun [1 ,2 ]
Zhou, Yanhan [6 ]
Han, Jinghong [3 ]
Yu, Yingzhe [3 ]
Li, Bingsong [4 ]
Xu, Chunming [5 ]
Zhang, Jun [3 ]
Zhu, Xiaobo [1 ,2 ]
机构
[1] The Second Clinical Medical College, Cheeloo College of Medicine, Shandong University, Shandong, Jinan,250033, China
[2] Children's Medical Center, The Second Hospital of Shandong University, Jinan,250033, China
[3] School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinica
[4] Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan,250012, China
[5] Xinjiang Medical University, Urumqi, China
[6] School of Mechanical Engineering, Shandong University, Jinan, China
基金
中国国家自然科学基金;
关键词
Cell death - Gene therapy - Lung cancer;
D O I
10.1016/j.ijbiomac.2024.137862
中图分类号
学科分类号
摘要
An increasing number of expression quantitative trait loci (eQTLs) have been linked to tumorigenesis. In this study, we used Mendelian randomization (MR) to identify a novel cancer susceptibility gene, Trimethylguanosine Synthase 1 (TGS1). TGS1-induced hypermethylation at the 5′ end of human telomerase RNA (hTR) impedes hTR accumulation, decreasing telomerase assembly factor levels and thus limiting telomere elongation, a crucial factor in tumor progression. Despite its significant role in cancer development, the TGS1-cancer relationship requires further experimental validation and bioinformatics analysis. To bridge this knowledge gap, we performed a comprehensive pan-cancer study using MR to evaluate TGS1's involvement in cancer progression. Leveraging data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), we analyzed TGS1's role in 33 tumor types. The results indicated higher TGS1 expression in most tumors, with a significant correlation to patient prognosis. We also noted variations in TGS1 phosphorylation at different sites and a strong link between TGS1 expression and the infiltration of various immune cells. In addition, our enrichment analysis of TGS1-associated genes shed light on the molecular mechanisms involved. The study also highlighted TGS1's significant role in cellular apoptosis. Overall, our findings offer an in-depth analysis of TGS1's oncogenic roles across multiple tumor types and underscore its potential as an oncogene, biomarker, and gene therapy target in diverse cancers. © 2024 The Author(s)
引用
收藏
相关论文
共 50 条
  • [41] Multi-omics pan-cancer analysis reveals the prognostic values and immunological functions of PPA2, with a spotlight on breast cancer
    Zhang, Jia-Ning
    Yang, Bei-Bei
    Li, Lin-Wei
    Xu, Hao
    Wang, Bin
    Yi, Zi-Lu
    Zhou, Xi-Rui
    Liu, Hong
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [42] Pan-Cancer Analysis Reveals SOX2 as a Promising Prognostic and Immunotherapeutic Biomarker Across Various Cancer Types, Including Pancreatic Cancer
    Ding, Yuntao
    Wang, Huizhi
    Wang, Qiaowei
    Jiang, Han
    Li, Zhangzuo
    Yu, Zhengyue
    Wang, Qi
    Xu, Min
    JOURNAL OF CANCER, 2024, 15 (01): : 251 - 274
  • [43] The prognostic values and immune characteristics of polo-like kinases (PLKs) family: A pan-cancer multi-omics analysis
    Shen, Chong
    Wang, Tong
    Li, Kai
    Fu, Chong
    Yang, Shaobo
    Zhang, Zhe
    Wu, Zhouliang
    Li, Zhi
    Li, Zhuolun
    Lin, Yuda
    Zhang, Yu
    Guo, Jian
    Fan, Zhenqian
    Hu, Hailong
    HELIYON, 2024, 10 (07)
  • [44] Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer
    Liu, Weihui
    Wei, Chengcheng
    He, Qingliu
    Chen, Zhaohui
    Zhuang, Wei
    Guo, Yihong
    Xue, Xueyi
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [45] Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy
    Lin, Zhengjun
    Wu, Yanlin
    Xiao, XunGang
    Zhang, Xianghong
    Wan, Jia
    Zheng, Tao
    Chen, Hongxuan
    Liu, Tang
    Tang, Xianzhe
    FRONTIERS IN GENETICS, 2022, 13
  • [46] Multi-omics analysis identifies BCAT2 as a potential pan-cancer biomarker for tumor progression and immune microenvironment modulation
    Qixuan Cao
    Jie Fan
    Jian Zou
    Wei Wang
    Scientific Reports, 14 (1)
  • [47] Systematic Pan-Cancer Analysis Identifies CDK1 as an Immunological and Prognostic Biomarker
    Yang, Yaqi
    Liu, Qin
    Guo, Xiyuan
    Yuan, Qing
    Nian, Siji
    Kang, Pengyuan
    Xu, Zixi
    Li, Lin
    Ye, Yingchun
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [48] Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker
    Yang, Wei
    Liu, Zhidong
    Liu, Ting
    CELLULAR SIGNALLING, 2024, 117
  • [49] Systematic pan-cancer analysis insights into ICAM1 as an immunological and prognostic biomarker
    Yang, Chunjiao
    Ni, Bingqiang
    Shen, Ling
    Li, Zhenlong
    Zhou, Lu
    Wu, Huayun
    Zhang, Yuzhe
    Liu, Ling
    Liu, Jiao
    Tian, Liansheng
    Yan, Lirong
    Jin, Xin
    FASEB JOURNAL, 2024, 38 (13):
  • [50] Comprehensive pan-cancer analysis reveals ENC1 as a promising prognostic biomarker for tumor microenvironment and therapeutic responses
    Zhenyu Cao
    Jinfeng Zhu
    Zicheng Wang
    Yuhuai Peng
    Liyun Zeng
    Scientific Reports, 14 (1)